Vincristine-Induced Peripheral Neuropathy and Its Correlation with Mucocutaneous Pigmentation Changes
DOI:
https://doi.org/10.5281/zenodo.22644289Keywords:
vincristine-induced peripheral neuropathy, mucocutaneous hyperpigmentation, chemotherapy-induced neurotoxicity, CYP3A5 pharmacogenomics, melanonychiaAbstract
Background: Vincristine-induced peripheral neuropathy (VIPN) is the classic dose-limiting toxicity of vincristine-containing
chemotherapy, while mucocutaneous pigmentation changes-serpentine supravenous hyperpigmentation, melanoderma, and
transverse melanonychia-are separately documented cutaneous accompaniments of the same regimens. Objective: To synthesize
the peripheral neuropathy and mucocutaneous pigmentation literatures for vincristine-containing regimens and evaluate the
evidence for a mechanistic and clinical correlation between the two toxicities. Methods: A narrative review of case reports, cohort
studies, pharmacogenomic analyses, and systematic reviews addressing VIPN incidence, grading, and risk factors, and
vincristine-associated cutaneous, nail, and oral pigmentation, with attention to regimen overlap, temporal course, and shared
pharmacogenomic determinants. Findings: VIPN occurs in approximately one-third of patients by routine CTCAE grading but is
identified in up to 86 percent using structured multi-domain instruments such as the pediatric-modified Total Neuropathy Score,
and shows consistent cumulative-dose dependence and pharmacogenomic modulation by CYP3A5 and ABCB1 variants.
Mucocutaneous pigmentation has been reported within the same vincristine-containing regimens-VAD, hyper-CVAD, R-CHOP, and
pediatric leukemia consolidation-on a broadly similar timescale of weeks to months, and both toxicities plausibly arise from
vincristine's disruption of microtubule-dependent intracellular transport in peripheral axons and melanocytes, respectively. No
study has yet prospectively assessed both toxicities with validated instruments in the same cohort. Conclusions: The correlation
between vincristine-induced peripheral neuropathy and mucocutaneous pigmentation is mechanistically plausible and supported
by convergent shared-regimen, shared-timing, and shared-pharmacogenomic evidence, but remains a testable hypothesis rather
than an established relationship; prospective studies pairing structured neuropathy scoring with systematic dermatologic
assessment, stratified by CYP3A5/ABCB1 genotype, are needed.
References
Triarico S, Romano A, Attinà G, Capozza MA, Maurizi P, Mastrangelo S, Ruggiero A (2021) Vincristine-Induced Peripheral Neuropathy (VIPN) in Pediatric Tumors: Mechanisms, Risk Factors, Strategies of Prevention and Treatment. International Journal of Molecular Sciences, 22(8):4112, DOI:10.3390/ijms22084112.
Lindhard Madsen M, Due H, Ejskjær N, Jensen P, Madsen J, Dybkær K (2019) Aspects of vincristine-induced neuropathy in hematologic malignancies: a systematic review. Cancer Chemotherapy and Pharmacology, 84(3):471-485, DOI:10.1007/s00280-019-03884-5.
Alwhaibi AM, Alshamrani AA, Alenazi MA, Altwalah SF, Alameel NN, Aljabali NN, Alghamdi SB, Bineid AI, Alwhaibi M, Al Arifi MN (2023) Vincristine-Induced Neuropathy in Patients Diagnosed with Solid and Hematological Malignancies: The Role of Dose Rounding. Journal of Clinical Medicine, 12(17):5662, DOI:10.3390/jcm12175662.
Schouten SM, van de Velde ME, Kaspers GJL, Mokkink LB, van der Sluis IM, van den Bos C, Hartman A, Abbink FCH, van den Berg MH (2020) Measuring vincristine-induced peripheral neuropathy in children with cancer: validation of the Dutch pediatric-modified Total Neuropathy Score. Supportive Care in Cancer, 28(6):2867-2873, DOI:10.1007/s00520-019-05106-3.
Marcoux D, Anex R, Russo P (2000) Persistent serpentine supravenous hyperpigmented eruption as an adverse reaction to chemotherapy combining actinomycin and vincristine. Journal of the American Academy of Dermatology, 43(3):540-546, DOI:10.1067/mjd.2000.106239.
Dasanu CA, Vaillant JG, Alexandrescu DT (2006) Distinct patterns of chromonychia, Beau's lines, and melanoderma seen with vincristine, adriamycin, dexamethasone therapy for multiple myeloma. Dermatology Online Journal, 12(6):10, DOI:10.5070/D321m795kv.
Yamamoto J, Fujimura T, Asano Y (2024) Atypical bilateral hyperpigmented macules on the lower legs possibly due to cyclophosphamide. Case Reports in Dermatology, 17(1):14-18, DOI:10.1159/000543124.
Tisack A, Mohammad TF (2024) Drug-Induced Pigmentation: A Review. Drugs, 84(9):1071-1091, DOI:10.1007/s40265-024-02062-z.
Egbelakin A, Ferguson MJ, MacGill EA, Lehmann AS, Topletz AR, Quinney SK, Li L, McCammack KC, Hall SD, Renbarger JL (2011) Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia. Pediatric Blood & Cancer, 56(3):361-367, DOI:10.1002/pbc.22845.
Skiles JL, Chiang C, Li CH, Martin S, Smith EL, Olbara G, Jones DR, Vik TA, Mostert S, Abbink F, Kaspers GJ, Li L, Njuguna F, Sajdyk TJ, Renbarger JL (2018) CYP3A5 genotype and its impact on vincristine pharmacokinetics and development of neuropathy in Kenyan children with cancer. Pediatric Blood & Cancer, 65(3):e26854, DOI:10.1002/pbc.26854.
Yang QY, Hu YH, Guo HL, Xia Y, Zhang Y, Fang WR, Li YM, Xu J, Chen F, Wang YR, Wang TF (2021) Vincristine-Induced Peripheral Neuropathy in Childhood Acute Lymphoblastic Leukemia: Genetic Variation as a Potential Risk Factor. Frontiers in Pharmacology, 12:771487, DOI:10.3389/fphar.2021.771487.
Shan J, Obiakor BC, Cheng J, Francois RA, Dobry AS (2024) Serpentine supravenous hyperpigmentation induced by chemotherapy: a systematic review. Archives of Dermatological Research, 316(6):215, DOI:10.1007/s00403-024-03057-2.
Li T, Trinh T, Bosco A, Kiernan MC, Goldstein D, Park SB (2024) Characterising vincristine-induced peripheral neuropathy in adults: symptom development and long-term persistent outcomes. Supportive Care in Cancer, 32(5):278, DOI:10.1007/s00520-024-08484-5.
Verma P, Devaraj J, Skiles JL, Sajdyk T, Ho RH, Hutchinson R, Wells E, Li L, Renbarger J, Cooper B, Ramkrishna D (2020) A Metabolomics Approach for Early Prediction of Vincristine-Induced Peripheral Neuropathy. Scientific Reports, 10(1):9659, DOI:10.1038/s41598-020-66815-y.
Lopes M, Jordão C, Grynszpan R, Sodré C, Ramos-e-Silva M (2013) Chromonychia secondary to chemotherapy. Case Reports in Dermatology, 5(2):163-167, DOI:10.1159/000351874.
Parakh A, Gupta A, Dubey AP (2008) Chemotherapy induced nail changes. Indian Journal of Dermatology, 53(4):204, DOI:10.4103/0019-5154.44804.
Sawaki A, Miyazaki K, Yamaguchi M, Takeuchi T, Kobayashi K, Imai H, Tawara I, Ono R, Nosaka T, Katayama N (2020) Genetic polymorphisms and vincristine-induced peripheral neuropathy in patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone therapy. International Journal of Hematology, 111(5):686-691, DOI:10.1007/s12185-020-02832-x.
Kumar S, Bhattacharjee R, Kambhampati SB, Narang T, Kanwar AJ, Vinay K (2021) Chemotherapy-induced reticulate pigmentation in three Indian patients including a case in the pediatric age group. Indian Journal of Dermatology, Venereology and Leprology, 87(3):386-388, DOI:10.25259/IJDVL_216_20.
Bosilkovska M, Ing Lorenzini K, Uppugunduri CRS, Desmeules J, Daali Y, Escher M (2016) Severe Vincristine-induced Neuropathic Pain in a CYP3A5 Nonexpressor With Reduced CYP3A4/5 Activity: Case Study. Clinical Therapeutics, 38(1):216-220, DOI:10.1016/j.clinthera.2015.10.017.
Deutsch A, Leboeuf NR, Lacouture ME, McLellan BN (2020) Dermatologic Adverse Events of Systemic Anticancer Therapies: Cytotoxic Chemotherapy, Targeted Therapy, and Immunotherapy. American Society of Clinical Oncology Educational Book, 40:485-500, DOI:10.1200/EDBK_289911.
Alharithy R, Alotaibi K, Bin Salamah R, Altamimi R, Alqntash N, Alsarhan R, Khosyfan L, Alrowais S (2026) Drug induced hyperpigmentation: systematic review and meta-analysis. Frontiers in Medicine, 13:1674278, DOI:10.3389/fmed.2026.1674278.
